Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 8/20 | 0.50 |
| ▸ | MTOR | P42345 | 8/20 | 0.50 |
| ▸ | KDR | P35968 | 3/20 | 0.47 |
| ▸ | LCK | P06239 | 2/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.45 |
| ▸ | RAF1 | P04049 | 1/20 | 0.45 |
| ▸ | BRAF | P15056 | 1/20 | 0.45 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.45 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 9/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6485821 | 0.89 | PIK3CA (0.52) | PIK3CAMTORKDRLCKMAPK14 | |
| SCHEMBL6480431 | 0.80 | SYK (0.54) | SYKSCN9A | |
| SCHEMBL6479687 | 0.79 | DRD2 (0.52) | PIK3CAMTORKDRLCKMAPK14 | |
| SCHEMBL6479199 | 0.78 | PIK3CA (0.52) | PIK3CAMTORKDRLCKMAPK14 | |
| SCHEMBL6478557 | 0.77 | PIK3CA (0.47) | PIK3CAMTORKDRLCKMAPK14 | |
| SCHEMBL6487099 | 0.76 | PIK3CA (0.46) | PIK3CAMTORKDRLCKMAPK14 | |
| SCHEMBL6478952 | 0.75 | KDR (0.74) | PIK3CAMTORKDRLCKMAPK14 | |
| SCHEMBL6497316 | 0.75 | SYK (0.53) | KDRSYKSCN9A | |
| SCHEMBL6493998 | 0.74 | PIK3CA (0.46) | PIK3CAMTORKDRLCKMAPK14 | |
| SCHEMBL6479848 | 0.71 | PIK3CA (0.54) | PIK3CAMTORKDRLCKMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6864255-B2 | Substituted triazinyl amide derivatives and methods of use | AMGEN INC. (US) | 2005-03-08 | — | — | US | disclosed |
| EP-1385833-A1 | TRIAZINYL AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS | Amgen Inc. (US) | 2004-02-04 | — | — | EP | disclosed |
| US-20030087908-A1 | Substituted triazinyl amide derivatives and methods of use | AMGEN INC. | 2003-05-08 | — | — | US | disclosed |
| WO-2002083654-A1 | TRIAZINYL AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS | AMGEN INC. (US) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087908-A1 | Substituted triazinyl amide derivatives and methods of use | FLT4, FLT1, VEGFA | PIK3CA 475/4885MTOR 1843/4885KDR 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.